Effectivenes of Citicoline On The Neurocognitive Improving In The Treatment of Acute Ischemic Stroke
Introduction: Stroke is a disease that affects the arteries leading to and within the brain. A stroke occurs when the blood supply to part of the brain is suddenly interrupted or when a blood vessel in the brain bursts, spilling blood into the spaces surrounding brain cells. Brain cells die when t...
Saved in:
Main Authors: | , , , |
---|---|
Format: | Book Section PeerReviewed |
Language: | English English English |
Published: |
Khon Kaen University
2015
|
Subjects: | |
Online Access: | http://repository.unair.ac.id/85622/2/C44.pdf http://repository.unair.ac.id/85622/1/Validasi%20C-44.pdf http://repository.unair.ac.id/85622/3/Effectiveness%20of%20Citicoline%20on%20the%20Neurocognitive%20Improving%20in%20the%20Treatment%20of%20Acute%20Ischemic%20Stroke.pdf http://repository.unair.ac.id/85622/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Universitas Airlangga |
Language: | English English English |
Summary: | Introduction: Stroke is a disease that affects the arteries leading to and within the brain. A stroke
occurs when the blood supply to part of the brain is suddenly interrupted or when a blood vessel in the
brain bursts, spilling blood into the spaces surrounding brain cells. Brain cells die when they no
longer receive oxygen and nutrients from the blood or there is sudden bleeding into or around the
brain. It is the main cause of death and a leading cause of disability all over the world. Nowadays, the
strategies of stroke therapy are to address in decreasing the progressivity of neuron damaged and to
attenuate the mortality of the disease. Neuroprotectant is one of therapeutic agent that intensively used
to reduce the occurrence of neuronal damage due to impaired blood flow to brain. The major of
neuroprotectant that use for acute ischemic stroke for inpatients in Dr. Soetomo Teaching Flospital
Surabaya is citicoline. There are available either for intravenous injection or oral tablet with
recommended dosage range from 500 to 2000 mg per day. However, the effectiveness of citicoline for
acute ischemic stroke at recent time as to enhance the improvement of neurological function is still
controversial and debatable.
Objectives: The aim of this study is to evaluate the effectiveness of citicoline on the neurocognitive
improving in the treatment of acute ischemic stroke for inpatients in Department of Neurology Dr.
Soetomo Teaching Hospital Surabaya.
Methods: The study was designed with retrospective method and data are obtained from document of
patient medical records from the period of 1st November 2013 until 28th February 2014. The clinical
outcome related with neurocognitive behavioral of acute ischemic stroke patients were measured by
National Institute of Health Stroke Scale (NIHSS).
Results: During research carry out, we obtained 61 acute ischemic stroke patients. 25 patients
(41%) received the standard therapy combined with^iticoline and 36 patients (59%) received standard
therapy only. Citicoline is given through intravena in dosage between 500 mg-2000 mg, twice to three
times daily. There are differences in the NIHSS improvement between the NIHSS initial and final
NIHSS of the group who were given standard therapy and the group who were given standard therapy
combined with citicoline (p < 0.001). Furthermore, there are differences in delta NIHSS comparisons
between group who were given standard therapy and the group who were given standard therapy
combined with citicoline, statistically significant (p = 0.004).
Conclusions: There are differences in effectiveness of neurocognitive behavioral improvement
between the using of standard therapy combined with citicoline and that with only standard therapy
towards patients in acute ischemic stroke when measured from clinic outcome using NIHS Scale |
---|